|
KYORIN Pharmaceutical Co., Ltd. is a pharmaceutical company engaged in the manufacturing and marketing of prescription drugs. The group structure includes two subsidiaries, Kyorin Remedio Co., Ltd. and Kyorin Pharmaceutical Group Factory Co., Ltd., which handle the production, testing, and distribution of pharmaceutical products. The company sources certain raw materials for its medicines from its associated company, Nihon Rikagaku Yakuhin Co., Ltd. Its business activities focus on the development and supply of therapeutic agents within the pharmaceutical sector. Summarised from the annual report, fiscal year ended Mar 2026 |
Industry Drug Manufacturers - General | Homepage kyorin-pharm.co.jp |
| Sector Healthcare | IR page kyorin-pharm.co.jp | |
|
Tags
pharmaceutical manufacturing, prescription drugs, drug distribution, pharmaceutical testing, Kyorin Remedio, Kyorin Pharmaceutical Group Factory, Nihon Rikagaku Yakuhin
|
Press page kyorin-pharm.co.jp/news |
Metrics
| Valuation | |
|---|---|
| Market cap | ¥ 66.42B |
| Market cap (USD) | $ 416.172M |
| P/E | 163.91 |
| PEG | — |
| P/BV | 0.48 |
| P/S | 0.53 |
| P/OCF | 5.45 |
| P/FCF | 7.72 |
| Dividend yield | 5.1% |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 2.5% |
| ROI | 2.1% |
| ROIC | 1.7% |
| Profit margin | 2.7% |
| Growth | |
|---|---|
| Revenue growing | No |
| Profits growing | No |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | -10.0% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | Yes |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 43 |
| Quality score | -22.2% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 126.257B | 130.087B | 119.532B | 113.27B | 105.534B | 102.904B | 109.983B | 113.62B | 110.64B | 115.373B | 119.483B | 113.121B | 111.4B | 107.031B |
| Net profit | 3.448B | 9.086B | 5.322B | 4.723B | 3.932B | 6.13B | 6.149B | 6.869B | 6.574B | 7.305B | 13.639B | 12.064B | 12.025B | 12.422B |
| Free cash flow | 2.405B | -2.787B | -4.697B | -7.397B | 3.656B | 65M | 4.522B | -4.029B | 6.583B | 13.741B | 3.795B | — | — | — |
| Figure | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price | 1.645K | 1.502K | 1.811K | 1.704K | 1.777K | 1.928K | 2.198K | 2.161K | 1.999K | 2.351K | 2.144K | 2.874K | 1.971K | 2.298K |
| Price performance 12m | 0.09 | -0.17 | 0.06 | -0.04 | -0.08 | -0.12 | 0.02 | 0.08 | -0.15 | 0.1 | -0.25 | 0.46 | -0.14 | — |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (JPY) | 46.2B | 47.9B | 52.6B | 47.4B | 40.4B | 41.7B | 47.3B | 47.7B | 47.6B | 47.3B |
| ↳ YoY growth | -4.4% | +3.6% | +10.0% | -9.9% | -14.8% | +3.0% | +13.5% | +0.9% | -0.3% | -0.5% |
| ↳ 5y CAGR | -3.5% | -2.0% | -0.2% | -1.9% | +0.1% | +3.2% | ||||
| Borrowings, current (JPY) | 1.32B | 957M | 20.9B | 10.4B | 10.3B | 10.3B | 10.3B | 20.3B | 7.6B | 2.87B |
| Borrowings, non-current (JPY) | 3.63B | 3.91B | 2.63B | 12.5B | 11B | 10.8B | 10.6B | 435M | 20.2B | 20.4B |
| Lease liabilities (JPY) | 576M | 510M | 456M | 679M | 546M | 488M | 341M | 211M | 604M | 468M |
| Cash and deposits (JPY) | 43.6B | 44.1B | 32B | 31.9B | 27.4B | 27B | 19.4B | 13.9B | 15B | 11.8B |
| Intangible assets (JPY) | 1.2B | 1.75B | 3.4B | 3.33B | 3.79B | 3.29B | 5.39B | 5.09B | 4.76B | 4.09B |
| Net debt (borrowings + leases - cash) (JPY) | -38.1B | -38.7B | -7.99B | -8.33B | -5.56B | -5.37B | 1.88B | 7.06B | 13.4B | 12B |
| Cash flow detail | ||||||||||
| Operating cash flow (JPY) | 16.4B | 10.5B | 340M | 7.74B | 5.19B | 6.35B | 2.01B | 1.55B | 3.51B | 6.38B |
| Purchases of property, plant and equipment (JPY) | -2.21B | -3.39B | -2.17B | -2.62B | -4.07B | -2.44B | -6.33B | -5.78B | -5.7B | -3.86B |
| Purchases of intangible assets (JPY) | -437M | -486M | -2.2B | -593M | -1.06B | -246M | -3.08B | -468M | -596M | -112M |
| Change in receivables (cash effect) (JPY) | 2.1B | -1.84B | -4.77B | 5.19B | 7B | -1.23B | -5.62B | -439M | 158M | 241M |
| Change in inventories (cash effect) (JPY) | 3.29B | 901M | -2.11B | -7.86B | -5.28B | -3.63B | -5.81B | -5.44B | -12.3B | -2.06B |
| Change in payables (cash effect) (JPY) | -634M | -834M | 1.18B | -1.66B | -2.79B | 3.91B | 2.87B | 502M | 1.25B | -1.08B |
| Dividends paid (cash effect) (JPY) | -4.32B | -4.33B | -5.07B | -4.35B | -4.35B | -3.77B | -3.02B | -3.01B | -3.02B | -3.3B |
| Interest paid (cash effect) (JPY) | -29M | -24M | -64M | -75M | -68M | -66M | -66M | -66M | -173M | -254M |
| Income taxes paid (cash effect) (JPY) | -3.77B | -1.66B | -3.48B | -1.51B | -1.9B | -1.25B | -2.07B | -2.98B | -1.32B | -2.87B |
| Operating cash flow before change in receivables (JPY) | 14.3B | 12.3B | 5.11B | 2.55B | -1.81B | 7.57B | 7.63B | 1.99B | 3.35B | 6.14B |
| Free cash flow (OCF - PPE - intangibles) (JPY) | 13.7B | 6.58B | -4.03B | 4.52B | 65M | 3.66B | -7.4B | -4.7B | -2.79B | 2.41B |
| Income detail | ||||||||||
| Research and development expense (JPY) | 13.6B | 14.2B | 10.8B | 11B | 9.7B | 8.9B | 10.9B | 8.02B | 10.5B | 12.1B |
| ↳ 5y CAGR | -5.7% | -8.1% | -5.2% | -5.8% | -0.9% | +4.4% | ||||
| Total comprehensive income (JPY) | 5.32B | 9.13B | 5.71B | 3.67B | 6.28B | 3.63B | 3.99B | 7.95B | 8.57B | 9.41B |
| Comprehensive income to owners (JPY) | 5.32B | 9.13B | 5.71B | 3.67B | 6.28B | 3.63B | 3.99B | 7.95B | 8.57B | 9.41B |
| Provision for credit losses (JPY) | — | — | — | — | — | — | — | — | — | 49M |
| Credit cost ratio (credit losses / average receivables) (%) | — | — | — | — | — | — | — | — | — | 0.1% |
| Reported | Jun 26, 2017 | Jun 25, 2018 | Jun 24, 2019 | Jun 22, 2020 | Jun 21, 2021 | Jun 24, 2022 | Jun 26, 2023 | Jun 24, 2024 | Jun 19, 2025 | Jun 18, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpTimely disclosures published on TDnet, newest first, titles as filed in Japanese. The link opens the disclosure on TDnet. Filings with EDINET (periodic reports, extraordinary reports, offerings, holding and buy-back reports), newest first, titles as filed in Japanese. The link opens the filing on EDINET. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding KYORIN Pharmaceutical Co., Ltd.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| DISV | 0.01% | 96,600 | $ 650.041K | Nov 12, 2026 |
| DFIS | 0.01% | 87,100 | $ 586.114K | Nov 12, 2026 |
| AVDS | 0.01% | 5,300 | $ 36.923K | Nov 16, 2026 |
| DXIV | 0.01% | 3,100 | $ 20.861K | Nov 12, 2026 |
| DFIC | 0.00% | 77,201 | $ 519.501K | Nov 12, 2026 |
| DFSI | 0.00% | 3,200 | $ 21.533K | Nov 12, 2026 |
| DFAX | 0.00% | 27,700 | $ 186.399K | Nov 12, 2026 |
| DFAI | 0.00% | 15,200 | $ 102.284K | Nov 12, 2026 |
| AVDE | 0.00% | 60,400 | $ 420.782K | Nov 16, 2026 |




制作の背景・目的
8月はエアコンの使用による冷気や空気の乾燥により咳の症状に悩まされる人が増える季節です。8週間以上続く長引く咳は「慢性咳嗽」と呼ばれ、日本では、20歳以上の2.89%にあたる約300万人が「慢性咳嗽」に罹患していると推計1,2) されています。患者さんは「夜眠れない」「仕事に集中できない」「周囲の視線が気になる」といった悩みを抱える一方で、「風邪が長引いているだけ」「元々の体質」と自己判断し、一人で抱え込んでしまっている現状があります。実際に、医師への相談割合も44%1)に留まっています。しかし、慢性咳嗽は医療機関で原因を特定し、適切な治療を行うことで改善が期待できるものです。
当社は、慢性咳嗽について広く知っていただくとともに、「長引く咳は治療できる可能性がある」という前向きなメッセージをお伝えすることを目的として、本動画を制作・公開いたしました。なお、本動画と同内容の冊子も2026年8月頃より全国の医療機関で配布しております。